FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLICA 10/726,38	ATION NO.:	
INFORMA	TION DISCLOSURE	E STATEMENT E	APPLICANT: Danishefsky et al		-
(Use	several sheets if neces	(STATE MAR 2 6 2004)	FILING DATE: December 2, 2003	GROUP:	
U.S. PATEN	T DOCUMENTS	The second second	<u> </u>		
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
40	*6,090,601	Gustafsson	July 18, 2000	435.	183
	*6,096,757	Bishop	August 1, 2000	514	290
	*6,117,659	Ashley	September 12, 2000	435	155
	*6,121,029	Schupp	September 19, 2000	435	183
	*6,211,412	Georg	April 3, 2001	568	309
	*6,221,641	Khosla	April 24, 2001	435	193
	*6,251,636	Betlach	June 26, 2001	435	76
	*6,262,107	Li	July 17, 2001	. 514	449
	*6,280,999	Gustafsson	August 28, 2001	.435	252.3
	*6,407,103	Nugiel et al.	June 18, 2002	514	232.8
	*6,489,314	Ashley et al.	December 3, 2002	514	183
	*6,498,257	Vite et al.	December 24, 2002	548	205
	*6,515,017	Li et al.	February 4, 2003	514	449
	*6,518,421	Li et al.	February 11, 2003	540	462
	*6,525,197	Furstner et al.	February 25, 2003	544	310
	*6,531,497	Nicolaou et al.	March 11, 2003	514	370
	*6,537,988	Lee	March 25, 2003	514	221
	*6,538,038	Pero et al.	March 25, 2003	514	731
	*6,544,544	Hunter et al.	April 8, 2003	424	424
	*6,576,651	Bandyopadhyay et al.	June 10, 2003	514	365
	*6,593,115	Vite et al.	July 15, 2003	435	134
	*6,596,875	White et al.	July 22, 2003	548	204
	*6,603,015	Georg et al.	August 5, 2003	548	203
	*6,603,023	Danishefsky et al.	August 5, 2003	549	346
	*6,605,599	Vite et al.	August 12, 2003	514	63
	*6,605,726	Mulzer et al.	August 12, 2003	548	202
	*6,610,736	Klar et al.	August 26, 2003	514	450
	0,010,730	Rial of al.	114545120,2005	V	

Hoefle et al.

*6,613,912

September 2, 2003

548

204

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	10/726,38	ATION NO.:	
			APPLICANT: Danishefsky et al		
(Use several sheets if necessary)		FILING DATE: December 2, 2003	GROUP:		
40	*6,624,310	Hoefle et al.	September 23, 2003	548	204
	*6,664,288	Pardee et al.	December 16, 2003	514	449
	*6,670,384	Bandyopadhyay et al.	December 30, 2003	514	365
V	*6,683,100	Van Hoogevest	January 27, 2004	514	365
U.S. PATEN	NT APPLICATIONS				
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:
70	*2002/0086812	Schweinfest et al.	July 4, 2002		
	*2002/0091269	Avery	July 11, 2002	,	
	*2002/0094991	Gallaher	July 18, 2002		
	*2002/0115686	Hoogevest	August 22, 2002		
	*2002/0119202	Hunter et al.	August 29, 2002		
	*2002/0137152	Santi et al.	September 26, 2002		
	*2002/0147197	Newman et al.	October 10, 2002		
	*2002/0156110	Arslanian et al.	October 24, 2002		
	*2002/0156289	Georg et al.	October 24, 2002		
	*2002/0164377	Hunter et al.	November 7, 2002		
	*2002/0165258	Lee	November 7, 2002		
	*2002/0165256	Hofmann et al.	November 7, 2002		
	*2002/0165257	Lee	November 7, 2002		
	*2002/0165265	Hunter et al.	November 7, 2002		
	*2002/0165415	Georg et al.	November 7, 2002	100	
	*2002/0169125	Leung et al.	November 14, 2002		
	*2002/0169135	Pardee et al.	November 14, 2002		
	*2002/0169190	Bandyopadhyay et al.	November 14, 2002		
	*2002/0177615	Bandyopadhyay et al.	November 28. 2002		
	*2002/0192778	Schupp et al.	December 19, 2002		
	*2002/0193361	Ashley et al.	December 19, 2002		
	*2002/0197261	Li et al.	December 26, 2002		
$\overline{}$	*2002/0198141	McChesney et al.	December 26, 2002		

FORM PT	O-1449 U.S. D	epartment of Commerce	ATTY. DOCKET:	IN RE
(REV. 8-83		and Trademark Office	2003080-0143	APPLICATION NO.:
			(SK-744-CON9) 10/726,386	
ll	(Use several sheets if necessary)		APPLICANT: Danishefsky et al	
(Us			FILING DATE:	GROUP:
			December 2, 2003	
Y0	*2003/0232968	Li et al.	December 18, 2003	
	*2003/0232837	Guzi et al.	December 18, 2003	
	*2003/0232416	Wong et al.	December 18, 2003	
	*2003/0235855	Cabral	December 25, 2003	
	*2003/0166507	Li et al.	September 4, 2003	
	*2003/0158412	Westermann et al.	August 21, 2003	
	*2003/0149281	Westermann et al.	August 7, 2003	·
	*2003/0147807	Li et al.	August 7, 2003	
	*2003/0144533	Iwasaki et al.	July 31, 2003	
	*2003/0144523	Klar et al.	July 31, 2003	
	*2003/0139460	Schwede et al.	July 24, 2003	
	*2003/0134883	Myles et al.	July 17, 2003	
	*2003/0130178	Li et al.	July 10, 2003	·
	*2003/0130170	Li et al.	July 10, 2003	
	*2003/0124055	Li et al.	July 3, 2003	
	*2003/0125362	Danishefsky	July 3, 2003	
	*2003/0113335	Li et al.	June 19, 2003	
	*2003/0114363	Li et al.	July 3, 2003	
	*2003/0114450	Santi et al.	June 19, 2003	
	*2003/0114504	Webster et al.	June 19, 2003	
	*2003/0114518	Li et al.	June 19, 2003	
	*2003/0105330	Danishefsky et al.	June 5, 2003	
	*2003/0109500	Pero et al.	June 12, 2003	
	*2003/0096381	Julien et al.	May 22, 2003	
	*2003/0087888	Regueiro-Ren et al.	May 8, 2003	·
	*2003/0073677	Lee	April 17, 2003	
	*2003/0073617	Li et al.	April 17, 2003	
	*2003/0073615	Li et al.	April 17,. 2003	
	*2003/0073205	Arslanian et al.	April 17, 2003	
	*2003/0069277	Danishefsky et al.	April 10, 2003	
\ \ (*2003/0060623	Vite et al.	March 27, 2003	
\sqrt{V}	*2003/0054977	Kumar et al.	March 20, 2003	

	FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: 2003080-0143	IN RE APPLICATION NO) .:
(IXE 4 : 0-02	Takin and Trauman Office		(SK-744-CON9)	10/726,386	- ••
INFORMA	TION DISCLOSURE	APPLICANT: Danishefsky et al			
(Use	e several sheets if necess	ary)	FILING DATE:	GROUP:	
			December 2, 2003		
70	*2003/0049841	Short et al.	March 13, 2003		
	*2003/0045711	Ashley et al.	March 6, 2003		
	*2003/0036515	Pardee et al.	February 20, 2003		
	*2003/0036177	Strohhacker	February 20, 2003		
1	*2003/0023082	Ashley et al.	January 30, 2003		
	*2003/0004338	Li et al.	January 2, 2003		
	*2003/0004209	Hunter et al.	January 2, 2003		
	*2003/0003094	Hunter et al.	January 2, 2003		
	*2003/0191089	Regueiro-Ren et al.	October 9, 2003		
	*2003/0187273	White et al.	October 2, 2003		
	*2003/0187039	Favreau et al.	October 2, 2003		
	*2003/0186983	Mastalerz et al.	October 2, 2003		
	*2003/0186965	Vite et al.	October 2, 2003		
	*2003/0185831	Cutler et al.	October 2, 2003		
	*2003/0180760	Basch et al.	September 25, 2003		
	*2003/0176710	Klar et al.	September 18, 2003		
	*2003/0176473	Taylor et al.	September 18, 2003		
	*2003/0176368	Danishefsky	September 18, 2003		
	*2003/0176320	Li et al.	September 18, 2003		
	*2003/0166507	Li et al.	September 4, 2003		
	*2004/0014982	Hoefle et al.	January 22, 2004		
	*2004/0014978	Klar et al.	January 22, 2004	·	
	*2004/0006087	Cutler et al.	January 8, 2004		
	*2003/0166507	Li et al.	September 4, 2003		
	*2004/0019088	Lichtner et al	January 29, 2004		
	*2004/0018598	Santi et al.	January 29, 2004		
	*2004/0014982	Hoefle et al.	January 22, 2004		
	*2004/0014978	Klar et al.	January 22, 2004	·	
V	*2004/0006087	Cutler et al.	January 8, 2004		
FOREIGN	PATENT DOCUMEN	TS			
Examiner's	Document No.	Country	Date	Translation	
Initials				Yes No	

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLICATION NO.: 10/726,386	
	ATION DISCLOSURE		APPLICANT: Danishefsky et al	
(Us	e several sheets if necesso	ary)	FILING DATE:	GROUP:
		December 2, 2003		
Yo	*DE 41 38 042	Germany	19 November 1991	·
1	*DE 41 38 042	Germary	19 November 1991	
	*DE 196 07 702	Germany	29 February 1996	
	*DE 196 36 343	Germany	30 August 1996	
	*DE 196 38 870	Germany	23 September 1996	
	*DE 196 47 580.5	Germany	18 November 1996	
	*DE 197 01 758	Germany	20 January 1997	
	*DE 197 07 506.1	Germany	25 February 1997	
	*DE 197 13 970	Germany	04 April 1997	
	*DE 197 20 312	Germany	15 May 1997	
1	*DE 197 26 627	Germany	17 June 1997	
	*DE 197 35 574	Germany	09 August 1997	
	*DE 197 35 575	Germany	09 August 1997	
	*DE 197 35 578	Germany	09 August 1997	
	*DE 197 44 135	Germany	29 September 1997	
	*DE 197 49 717	Germany	31 October 1997	
	*DE 197 51 200	Germany	13 November 1997	
	*DE 198 13 821	Germany	20 March 1998	
	*DE 198 21 954	Germany	15 May 1998	
	*DE 198 33 750	Germany	16 July 1998	
	*DE 198 46 493	Germany	09 October 1998	
	*DE 198 30 060	Germany	30 June 1998	
	*DE 198 49 464	Germany	21 October 1998	
	*DE 199 07 588	Germany	22 February 22, 1999	
	*DE 199 08 763	Germany	18 February 1999	
	*DE 199 08 765	Germany	18 February 1999	
	*DE 199 21 086	Germany	30 April 1999	
	*DE 199 23 001	Germany	13 May 1999	
	*DE 199 30 111	Germany	01 July 1999	
	*DE 199 54 228	Germany	04 November 1999	
	*DE 199 54 230	Germany	04 November 1999	
V	*DE 100 51 136	Germany	16 October 2000	

FORM PT		epartment of Commerce	ATTY. DOCKET:	IN RE
(REV. 8-83) Patent and Trademark Office		2003080-0143	APPLICATION NO.: 10/726,386	
INFODMA	TION DISCLOSURE S	TATEMENT	APPLICANT: Danishefsky et al	
	several sheets if necessa			
(030	(Use several sneeds if necessary)		FILING DATE: December 2, 2003	GROUP:
2/2	+DF 100 16 826	T.C	27 March 2000	
70	*DE 100 15 836	Germany		
	*DE 100 20 517	Germany	19 April 2000	
	*DE 100 20 899	Germany	20 April 2000	
	*EP 1 275 648	Europe	15 January 2003	
	*EP 1 201 666	Europe	02 May 2002	
	*EP 1 201 666	Europe	05 February 2002	
	*EP 1 186 606	Europe	13 March 2002	
	*EP 1 121 364	Europe	13 March 2002	
	*EP 1 087 975	Europe	27 August 2003	
	*EP 1 077 980	Europe	19 March 2003	
	*EP 1 042 327	Europe	17 September 2003	
	*EP 1 140 944	Europe	27 August 2003	
	*EP 1 340 498	Europe	03 September 2003	
	*EP 1 001 951	Europe	25 September 2002	
	*EP 0 975 638	Europe	07 August 2002	
<u> </u>	*EP 0 975 622	Europe	09 October 2002	
	*EP 0 903 348	Europe	No Publication	date
10	*EP 0 873 341	Europe	10 September 2003	
	*199 08 760	DE	24 August 2000	
	*199 08 767	DE	19 October 2000	
	*WO 2004/007476	PCT	22 January 2004	
	*WO 03/105828	PCT	24 December 2003	
	*WO 03/103712	PCT	18 December 2003	
	*WO 03/084536	PCT	16 October 2003	
	*WO 03/078411	PCT	25 September 2003	
	*WO 03/077903	PCT	25 September 2003	
	*WO 03/076445	PCT	18 September 2003	
	*WO 03/075899	PCT	18 September 2003	
	*WO 03/074521	PCT	12 September 2003	
	*WO 03/074053	PCT	12 September 2003	
	*WO 03/070170	PCT	13 February 2002	
1	*WO 03/057830	PCT	17 December 2002	

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET: 2003080-0143	IN RE APPLICATION NO.: 10/726,386	
INFORMA	TION DISCLOSURE S	TATEMENT.	(SK-744-CON9) 10/726,386 APPLICANT: Danishefsky et al	
	(Use several sheets if necessary)		FILING DATE:	GROUP:
(December 2, 2003	GROUP:
V0	*WO 03/057217	PCT	13 January 2003	
7,	*WO 03/053949	PCT	23 December 2002	
	*WO 03/049734	PCT	19 June 2003	
	*WO 03/045324	PCT	05 June 2003	
	*WO 03/042217	PCT	22 May 2003	
	*WO 03/029260	PCT	10 April 2003	· ·
	*WO 03/029195	PCT	10 April 2003	
	*WO 03/026744	PCT	03 April 2003	
	*WO 03/018002	PCT	06 March 2003	
	*WO 03/014068	PCT	20 February 2003	
	*WO 03/014063	PCT	20 February 2003	
	*WO 03/007924	PCT	30 January 2003	
	*WO 02/46196	PCT	13 June 2002	
	*WO 02/42432	PCT	30 May 2002	
	*WO 02/32844	PCT .	16 October 2001	
	*WO 02/30356	PCT	15 October 2001	
	*WO 02/098868	PCT	14 May 2002	
	*WO 02/080846	PCT	17 October 2002	
	*WO 02/074042	PCT	26 September 2002	
	*WO 02/072858	PCT	27 February 2002	
	*WO 02/072085	PCT	19 September 2002	
	*WO 02/067941	PCT	06 September 2002	
	*WO 02/066038	PCT	06 February 2002	
	*WO 02/066033	PCT	29 August 2002	
	*WO 02/062338	PCT	15 August 2002	
	*WO 02/060904	PCT	08 August 2002	
	*WO 02/058701	PCT	01 August 2002	
	*WO 02/058700	PCT	01 August 2002	
	*WO 02/058699	PCT	01 August 2002	
	*WO 01/81342	PCT	19 April 2001	
	*WO 01/81341	PCT	19 April 2001	·
-	*WO 01/73103	PCT	23 March 2001	

FORM PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		ATTY. DOCKET: 2003080-0143	IN RE APPLICATION NO.:	
INCODA A	TION DISCLOSURE	OT A THE RATE NAT	(SK-744-CON9) 10/726,386	
	(Use several sheets if necessary)		APPLICANT: Danishefsky et al	
(Ose several sneets if necessary)		FILING DATE:	GROUP:	
	1,	Tage	December 2, 2003	ψ
70	*WO 01/70716	PCT	12 March 2001	
	*WO 01/66154	PCT	09 March 2001	
	*WO 01/64650	PCT	01 March 2001	
	*WO 01/27308	PCT	06 October 2000	
	*WO 01/10412	PCT	02 August 2000	ļ
	*WO 01/92255	PCT	06 December 2001	
	*WO 01/83800	PCT	08 November 2001	
	*WO 01/07439	PCT	24 July 2000	
	*WO 00/71521	PCT	15 May 2000	
	*WO 00/66589	PCT	01 May 2000	
	*WO 00/58254	PCT	23 March 2000	
	*WO 00/57874	PCT	20 March 2000	
	*WO 00/50423	PCT	17 February 2000	
	*WO 00/49021	PCT	18 February 2000	
	*WO 00/49020	PCT	18 February 2000	
	*WO 00/49019	PCT	18 February 2000	
	*WO 00/047584	PCT	11 February 2000	
	*WO 00/39276	PCT	21 December 1999	
	*WO 00/37473	PCT	20 December 1999	
	*WO 00/31247	PCT	19 November 1999	
	*WO 00/00485	PCT	30 June 1999	
	*WO 99/67253	PCT	21 June 1999	
	*WO 99/67252	PCT	21 June 1999	
	*WO 99/66028	PCT	16 June 1999	
	*WO 99/65913	PCT	18 June 1999	
	*WO 99/59985	PCT	14 May 1999	
	*WO 99/58534	PCT	07 May 1999	
	*WO 99/54330	PCT	14 April 1999	
	*WO 99/54319	PCT	05 April 1999	
	*WO 99/54318	PCT	05 April 1999	
-	*WO 99/43653	PCT	24 February 1999	
- \ //	*WO 99/43320	PCT	23 February 1999	

FORM PTO	0-1449 U.S. De	partment of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)	-		2003080-0143	APPLICATION NO.:	
,			(SK-744-CON9)	10/726,386	
INFORMAT	INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishef	sky et al	
(Use	several sheets if necessar	ν) .	FILING DATE:	GROUP:	
			December 2, 2003		
40	*WO 99/42602	PCT	17 February 1999		
1	*WO 99/39694	PCT	03 February 1999		
	*WO 98/54966	PCT	04 June 1998		
	*WO 98/25929	PCT	18 June 1998		
OTHER DO	CUMENTS				
Examiner's Initials	Citation (Including Aut				
10			ule Stabilizing Antitumor rpless' Asymmedtric Epo		
			ures - a new class of micr		
			mica et Biophysica Acta,		
į	*Altmann, et al., "Epothilones and Their Analogs-Potential New Weapons in the Fight Against Cancer", Chimia, 54: 612-621, 2000. *Altmann, et al., "Synthesis and Biological Evaluation of Highly Potent Analogues of Epothilones				
	B and D. Bioorg. Med. Chem. Lett., 10(24): 2765-2768, 2000.				
			ctures-A New Class of Mi ophys. Acta., 1470(3): M79		
			Analogs of Epothilones: (
1	Activity"	·		•	
	1999.		San Francisco, CA, Marc		
	*Altmann, et al., "Synth (Angew. Chem. Int. Ed.		uation of Aza-Epothilone	s" ChemBioChem	
			its: A Growing Class of I	mportant Anticancer	
	Drugs" Curr. Opin. Che				
1	*Appendino, et al., "The 11(9): 678-696, 1998.	Synthesis of Epothilon	es: Highlights from a Yea	r's Race", Chemtracts,	
	•	•	from Modified Polyketid	=	
			hus" J. Nat. Prod., 65: 10 on Tumor Cells", Cancer		
			cular-Targeted Therapies		
	Metastatic Breast Cance	er Review, 4-15, 2002.			
·	*Baik, et al., Diastereos J.Am. Chem. Soc., 123: 5		ed Aldol and Michael Cyc	loreductions,	
	*Balog, et al., "A Novel	Aldol Condensation wi	th 2-Methyl-4-Pentenal argew. Chem. Int. Ed. 37(19)	nd Its Application to an): 2675-2678, 1998.	
	*Balog, et al., "Total Sy	nthesis of Epothilone A	, Angew Chem. Int. Ed. 6	1: 2801-2803, 1996.	
V	*Bellemin-Laponnaz, et al., "The Kinetic Resolution of Allylic Alchols by a Non-Enzymatic Acylation Catalyst: Application to Natural Product Synthesis" Chem. Commun., 12: 1009-1010,				

FORM PT	O-1449 U.S. Department of Commerce	ATTY. DOCKET:	IN RE		
(REV. 8-8	Patent and Trademark Office	2003080-0143	APPLICATION NO.:		
		(SK-744-CON9)	10/726,386		
INFORM	ATION DISCLOSURE STATEMENT	APPLICANT: Danishefs	sky et al		
(Us	e several sheets if necessary)	FILING DATE:	GROUP:		
		December 2, 2003			
70	2000.	, , , , , , , , , , , , , , , , , , , ,			
70	*Bertinato, et al., "Studies Toward a Synthesis of	of Epothilone A: Stereocor	trolled Assembly of the		
	Acyl Region and Models for Macrocyclization"	-	·		
	*Beyer, et al., "Metabolic Diversity in Myxobac 195, 1999.				
	*Biswas, et al., Highly Concise Routes to Epoth Epothilone 490, J. Am. Chem. Soc., 124: 9825-9	832, 2002.			
	*Blum, et al., "In vivo Metabolism of Epothilone B in Tumor-Bearing Nude Mice: Identification				
	of Three New Epothilone B Metabolites by Cap				
	Spectrometry/Tandem Mass Spectrometry" Rap				
	*Bocci, et al., Protracted Low-Dose Effects on I in Vitro Reveal a Selective Antiangiogenic Win Cancer Research, 62: 6938-6943, 2002.				
	*Boddy, et al., Epothilone C. Macrolactonization and Hydrolysis Are Catalyzed by the Isolated				
	Thioesterase Domain of Epothilone Polyketide				
	*Bode, et al., "Stereoselective Syntheses of Epo				
	Cycloaddition"				
	J. Am. Chem. Soc., 123(15): 3611-3612, 2001.	111 A 179 ' NT' 'I	0 11 0 11 11/1		
•	*Bode, et al., Stereoselective Syntheses of Epot and Related Studies" J. Org. Chem., 66(19): 64	10-6424, 2001.			
	*Bornscheuer, et al., "Directed Evolution of an Key Intermediate in the Synthesis of Epothilone				
	*Borzilleri, et al., "A Novel Application of a Pd	(0)-Catalyzed Nucleophilic	Substitution Reaction		
	to the Regio and Stereoselective Synthesis of La	ctam Analogues of the Ep	othilone Natural		
	Products"				
	J. Am. Chem. Soc., 122(37): 8890-8897, 2000.	thursen Dlave a Maglicible	Dala in Madiating the		
	*Broker, et al., Late Activation of Apoptotic Par Cytotoxic Effects of Discodermolide and Epoth				
	Cancer Research, 62: 4081-4088, 2002.	none D in 14011-5111aii Cell	Duile Coulon Coulo		
	*Brummond, et al "A Novel Application of a F	d(0)-Catalyzed Nucleophi	lic Substitution Reaction		
	to the Regio- and Stereoselective Synthesis of L				
	Products"	-			
	Chemtracts, 14(7): 401-404, 2001.				
	*Buck, et al., "Epothilones: A New Class of Mic		ts with a Taxol-Like		
	Mechanism of Action, Chemtracts, 11: 671-677		as A Dound to Dubuling		
	*Carlomagno, et al., "The High-Resolution Solu An Understanding of the Structure-Activity Rel				
	Agents" Angew. Chem. Int. Ed., 42: 2511-2515, 2		Jiano Ol I Milliamilloi		
	*Carlomagno, et al., "Derivation of Dihedral Ar		Dipolar Cross-		
	Correlated Relaxation Rates: A C-C Torsion Inv				
	Bound to Tubulin" Angew. Chem. Int. Ed., 42: 251	- -	•		
	*Carreira, E., "Discovery and Study of New Re-		tions in Complex		
	Molecule Assembly" Chimia, 55(10): 818-820, 2001.				

FORM	110 D	A MONTE DO CALET	DIDD
FORM PTO	•	ATTY. DOCKET:	IN RE
(REV. 8-83)	Patent and Trademark Office	2003080-0143	APPLICATION NO.:
		(SK-744-CON9)	10/726,386
	TION DISCLOSURE STATEMENT	APPLICANT: Danishefs	sky et al
(Use	several sheets if necessary)	FILING DATE:	GROUP:
		December 2, 2003	
10	*Casas, et al BINOLAM, a Recoverable Chiral Catalysis: The Asymmetric Synthesis of Cyanol		
 	*Chappell, et al., "En Route to a Plant Scale Syr		
	Desoxyepothilone B" Org. Letter. 2(11): 1633-	1636, 2000.	
	*Chen, et al "Epothilone Biosynthesis: Assem	- ·	carboxy Starter Unit on
	the EpoB Subunit" Chem. Biol., 8(9): 899-912, 2	2001.	1 12 14
	*Chevalier, Epothilones: A New Generation of I		
	*Chou, Desoxyepothilone B is curative against by paclitaxel <i>Proc. Natl. Acad. Sci</i> , 95: 15798-1580:	2, 1998.	
	*Chou, et al., "The Synthesis, Discovery, and D	evelopment of a Highly Pr	omising Class of
	Microtubule Stabilization Agents: Curative Effe		
	Tumor Xenografts in Nude Mice" <i>Proc. Natl. Ac</i> *Chou, et al., "Desoxyepothilone B: An Efficaci	caa. Sci.,98(14): 8113/811	δ, 2001. Antitumor Agent with a
	Promising In Vivo Profile Relative to Epothione		
-	*Chou, et al Desoxyepothilone B: An efficacion		
	promising in vivo profile relative to epothilone I		
	*Claus, E. et al., "Synthesis of the C1-C9 Segme	ent of Epothilones", Tetral	nedron Letters
	38:8:1359-1362 (1997)	C	
	*Corey, et al., "Chemistry of Diimide. Some Ne Bonds" <i>Tetrahedron Lett.</i> 347-352 1961.		
	*Correia, et al., "Physiochemical Aspects of Tul	oulin-Interacting Antimitor	tic Drugs" Curr. Pharm.
	Des., 7(13): 1213-1228, 2001.	12 Materia 297: 229 220	1007
	*Cowden, et al., "Cancer Drugs-Better than Tax		
	*Danishefsky, et al., "Insights into Long-Range Condensations: A Practical Total Synthesis of I. J. Am. Chem. Soc., 123(22): 5249-5259, 2001.		Stereochemistry of Aldol
	*Danishefsky, et al., "On the Interactivity of Co.	mplex Synthesis and Tume	or Pharmacology in the
	Drug Discovery Process: Total Synthesis and C Epothilones" J. Org. Chem., 66(12): 4369-4378,	omparative In Vivo Evalu	
	*Danishefsky et al., "Chemical Synthesis and Bi	iological Studies of the Ep	
	Stabilizing Agents with Enhanced Activity Agai		ell Lines and Tumors"
	Chem. 21st Century, Ed. Keinan, Wiley-VCH Ver	rlag, 8-36 2001	- Antituman Anna
	*Danishefsky, et al., "En Route to a Plant Scale 12,13- Desocyepothilone B" Org. Letters, 2: 163	33-1636, 2000.	
	*Danishefsky, et al., "On the Total Synthesis and		
,	15 (S) Aza-dEpoB: A Mitsunobu Inversion at C	15 in Pre-Epothilone Fragi	ments" Urg. Letters, 2:
	1637-1639, 2000. *Danishefsky, et al., "The Total Synthesis and A	Antitumor Activity of 12 1	3-Desoxyenothilone F
	An Unexpected Solvolysis Problem at C15, Med		
	Chem., 65(20): 6525-6533, 2000.		
11/	*Danishefsky, et al "Subtle Variations in the L		
V	Information: Matched and Mismatched Aldol R	Leactions" Angew. Chem. I	nt. Ed., 39: 4505-4508,

FORM PTO	1-1449 U.S. Department of Co	ommerce	ATTY. DOCKET:	IN RE			
(REV. 8-83)	Patent and Trademark	Office	2003080-0143	APPLICATION NO.:			
,			(SK-744-CON9)	10/726,386			
	TION DISCLOSURE STATEMENT		APPLICANT: Danishe	fsky et al			
(Use	several sheets if necessary)		FILING DATE:	GROUP:			
			December 2, 2003				
· 40	2000.						
	*Danishefsky, et al., "Dianion Equival Epothilone B" Tetrahedron Letters, 40		• •	oionate Domain of			
	*Danishefsky, et al., "Remarkable Lon Condensation" <i>Tetrahedron Letters</i> , 40	0: 2267-227	70, 1999.				
	*Danishefsky, et al., "The microtubule						
	derivatives induce mitotic arrest and ap		human prostate cancer of	cells." Prostate Cancer			
	*Danishefsky, "New Chemical synthes	9. sia of the D	ramising Canaar Chama	therapautic A cent 12 13-			
	Desoxyepothilone B: Discovery of a S	Sis of the Fi Sumrising I	ong-Range Effect on the	e Diastereoselective of an			
	Aldol Condensation." J. Am. Chem. So			o Diable Cooperation volume			
	*Danishefsky, et al., "A Novel Aldol C			tenal and the Application			
	to an Improved Total Synthesis of Epo	othilone B",	Angew. Chem. Int. Ed.	37: 2675, 1998.			
,	*Danishefsky, et al., "Epothilones: Mic						
	Against Multidrug-Resistant Cell Lines and Tumors." Actualites de Chimie Therpaeutique, Vingt-						
	cinqueme serie, Paul Ehrlich Lecture, Societe de Chimie Therapeutique, Elsevier, Paris, New						
	York, 25: 187-206, 1999. *Danishefsky, et al., "The Synthesis and Evaluation of 12,13-Benzodesoxyepothilone B: a Highly						
	Convergent Route." Tetrahedron Letters, 40: 6895-6898, 1999.						
	*Danishefsky, et al., "Complex Target	*Danishefsky, et al., "Complex Target Oriented Synthesis in the Drug Discovery Process: A Case					
	History in the dEpoB Series" J. Org. C	es" J. Org. Chem., 64: 8434-8456, 1999.					
	*Danishefsky, et al., "Desoxyepothilone B is Curative Against Human Tumor Xenografts that are						
	Refractory to Pacilitaxel", Proc. Nat. Acad. Sci., 95: 15798, 1998.						
	*Danishefsky, et al., "Remote Effects in Macrolide Formation Through Ring Forming Olefin						
	Metathesis: An Application to the Synthesis of Fully Active Epothilone Congeners", J. Am. Chem. Soc. 119: 2733, 1997.						
	*Danishefsky, et al., "Total Synthesis of (-) - Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure - Activity Relationships of the Epothilones", Angew. Chem. Int. Ed. 36: 757, 1997.						
	*Danishefsky, et al., "Structure-Activity Relationships of the Epothilones and the First in Vivo Comparison with Paclitaxel", Angew. Chem. Int. Ed., 7: 824-826, 1997.						
	*De Brabander, et al., "Towards a Syn and C(7)-C(12) Fragments", Synlett, 7:	: 824-826,	1997.				
	*De Brabander, et al., "Towards a Syn	*De Brabander, et al., "Towards a Synthesis of Epothilone A", Synlett, 3:328, 1998.					
	*De Brabander, et al., "Towards a Synthesis of Epothilone A. Rapid Assembly of the C(1)-C(6) and C(7)-C(12) Fragments" Synlett, 6: 692, 1998.						
	*Delbaldo, et al., Nouveaux medicamenets dans le cancer bronchique La Presse Medicate, 31: 802-809, 2002.						
	*Denmark, et al., "Cyclopropanation w Complexes", J. Org. Chem. 62:3375-3		nethane and Bis(Oxazol	ine) Palladium(II)			
V	*Duthaler, et al., "Enantioselective Ald Carbohydrate Complexes", Angew. Ch	dol Reactio					

FORM PTC	•		ATTY. DOCKET:	IN RE	
(REV. 8-83)	Patent and Trademark O		2003080-0143	APPLICATION NO.:	
	OVAN ALGOV AGUIDE OT A TEMENT	<u> </u>	(SK-744-CON9) 10/726,386		
	FION DISCLOSURE STATEMENT		APPLICANT: Danishefs	sky et al	
(Use	several sheets if necessary)		FILING DATE:	GROUP:	
			December 2, 2003		
1	*End, et al., "Synthetic Epothilone Ana				
70	the Heterocyclic Side-Chain-Synthesis a		•		
1	ECSOC-4, 1999, 2000, Meeting Date 19				
	Molecular Diversity Preservation Intern				
	*Essayan, et al., "Successful Parenteral I 97: 42-46, 1996.	Desensitiz	Zation to Pacifiaxei, J. A	itergy Clin. Immunot.	
	*Finley, et al., "Metathesis vs. Metastasi	is: The Ch	nemistry and Biology of	The Epothilones". Chem	
	Ind. 24: 991-996, 1997.		ionnous une Dierogy er	-	
	*Florsheimer, et al., "Epothilones and T	heir Analo	ogues-A New Class of Pr	romising Microtubule	
	Inhibitors"				
	Expert Opin. Ther. Pat., 11(6): 951-968,				
	*Frykman, et al., Control of Secondary I			via Modulation of the	
	Dissolved Oxygen Tension, Biotechnol. Prog., 18: 913-920, 2002.				
	*Fürstner, "Olefin Metathesis and Beyond", Angew. Chem. Int. Ed. Engl. 39: 3013-3043, 2000.				
1	*Furstner, et al., "Concise Total Synthes	ses of Epo	othilone A and C Based o	n Alkyne Metathesis"	
	Chem. Commun., 12: 1057-1059, 2001.	Da Nava	Magazia Unbrida aa	Potential Anticoncer	
l	*Geng, et al., "Design and Synthesis of De Novo Macrocyclic Hybrids as Potential Anticancer Agents" Abstr. PapAm. Chem. Soc., 221 st , MEDI-130, 2001				
	*Georg, et al., "Studies Toward the Synthesis of Epothilone Affinity Labels" Book of Abstracts,				
	219th ACS National Meeting, San Francisco, CA, March 26-30, MEDI-075, 2000.				
	*Gerlach, et al., "Synthesis of the C(7)-C	C(17) Seg	ment of Epothilones by a	10-Membered Ring	
	Closing Metathesis Reaction", Synlett, 1	0 : 1108-1	110, 1998		
	*Gerth, et al., "Studies on the Biosynthesis of Epothilones: the PKS and Epothilone C/D				
	Monooxygenase" J. Antibiot., 54(2): 144-148, 2001.				
	*Gerth, et al., "Epothilons A and B: Antifungal and Cytotoxic Compounds from Sorangium				
	cellulosum (Myxobacteria) Production, Physico-chemical and Biological Properties, <i>The Journal of Antibiotics</i> , 49-53, 1996.				
	*Gerth, et al., "Studies on the Biosynthe	sis of Enc	othilones: The Biosynthe	tic Origin of the Carbon	
	Skeleton" J. Antibiot, 53 (12): 1373-1377				
	*Giannakakou, et al., "A Common Phari	macophor			
	Basis for Drug Resistance Conferred by	Tubulin N	Mutations in Human Can	cer Cells" Proc. Natl.	
	Acad. Sci., 97(6): 2904-2909, 2000.			0.17.50	
	*Griffin, et al., Molecular Determinants				
	2L/TRAIL-induced Apoptosis of Human	n Ovanan	Cancer Cells, Gynecolog	gic Uncology, 69. 31-47	
	2003. *Grubbs, et al., "Ring-Closing Metathesis and Related Processes in Organic Synthesis" Acc. Chem.				
	Res. 28: 446-452, 1995.	no ana ivo	inion i roomsoo iii Organi		
	*Gupta, et al., Understanding Tubulin-Ta	axol Inter	actions: Mutations That	Impart Taxol Binding to	
	Yeast Tubulin PNAS, 100: 5394-6397, 2				
1	*Hamashima, et al., "Highly Enantiosele				
$\backslash \! \! /$	Acid-Lewis Base Bifunctional Catalyst"				

FORM PTO	-1449 U.S. Department of Commerce	ATTY. DOCKET:	IN RE		
(REV. 8-83)	Patent and Trademark Office	2003080-0143	APPLICATION NO.:		
(REV. 0-03)	ratent and Trademark Office	(SK-744-CON9)	10/726,386		
INFORMAT	TION DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al			
	several sheets if necessary)	FILING DATE:	GROUP:		
,	, ,,	December 2, 2003	GROOF.		
	*Hardt, et al., "New Natural Epothilones from S	<u> </u>	ains So ce90/B2 and So		
40	ce90/D13: Isolation, Structure Elucidation and	SAR Studies" J. Nat. Prod	<i>!</i> ., 64 (7): 847-856, 2001.		
	*Harris, et al., Complex Target-Oriented Synthesis in the Drug Discovery Process: A Case Histin the dEpoB Series J. Org. Chem., 64: 9434-8456, 1999.				
	*Harris, et al., New Chemical Synthesis of the F Desoxyepothilone B: Discovery of a Surprising an Aldol Condensation J. Am. Chem. Soc., 121: *Hayward, et al. "Total Synthesis of Rapamycin Macrocyclization Reaction", J. Am. Chem. Soc.,	Long-Range Effect on the 7050-7062, 1999. via a Novel Titanium-Med	Diastereoselectivity of		
	*He, et al., Novel Molcules that Interact with M Taxol Elsevier Science Ltd. DDT, 6: 1153-1164		tional Activity Similar to		
	*He, et al "Novel Molecules that Interact with to Taxol" <i>Drug Discovery Today</i> , 6(22): 1153-1		nctional Activity Similar		
	*He, et al., "A Common Pharmacophore for Taxol and the Epothilones Based on the Biological Activity of a Taxane Molecule Lacking a C-13 Side Chain" <i>Biochemistry</i> , 39(14): 3972-3978, 2000.				
	*He, Yun et al., "Total Synthesis and Biological Institute Order No.: DA9966202 From: Diss. A	Abstr. Int., B 2000, 61(3), 1	1414, 2000		
	*Hindpur, et al., "Total Synthesis of Epothilone	A" Tetrahedron Letters, 4	2 (42): 7341-7344, 2001.		
	*Hofle, et al., "Epothilone A-D and Their Thiaz Agents, Pure Appl. Chem., 71: 2019-2024, 1999				
	*Holland, M., "1. The Synthesis of a Cycloprop Reactions. 2. The Design and Synthesis of Nov Pennsylvania Order No.: DA9953544 From: I	el Epothilone Analogs" U	niversity of		
	*Holland, et al., "Design, Synthesis and Biologic Abstracts, 215th ACS National Meeting, Dallas,				
40	*Hosle, et al., Epothilone A and B – Novel 16-M Isolation, Crystal Structure, and Conformation 1 1569, 1996.				
V	*Hofle, et al., "N-Oxidation of Epothilone A-C Substituted Epothilones" Angew. Chem. Int. Ed.	, 38(13/14): 1971-1974, 19	999.		
-	*Inoue, et al., "Design and Synthesis of Taxoid-Epothilone Hybrids", Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27, ORGN-380.				
9	*Ivin, "Some Recent Applications of Olefin Me Catal. A: Chem, 133(1-2): 1998				
	*Jaenicke, L., "Epothilone from Amphora" Che	m. Unserer Zeit (German)	, 34(4): 257, 2000.		
V	*Jiang, et al., "Advances in Research on Novel Epothilones" Tianran Chanwu Yanjiu Yu Kaifa (

FORM PTO	-1449 U.S. Department of Commerce	ATTY. DOCKET:	IN RE		
(REV. 8-83)	Patent and Trademark Office	2003080-0143	APPLICATION NO.:		
		(SK-744-CON9) 10/726,386			
	TION DISCLOSURE STATEMENT	APPLICANT: Danishef	sky et al		
(Use s	several sheets if necessary)	FILING DATE:	GROUP:		
		December 2, 2003			
70	*Johnson, et al "Synthesis, Structure Proof, ar	d Biological Activity of E	pothilone		
	Cyclopropanes" Org. Lett, 2: 1537-1540, 2000				
	*Julien, et al., "Isolation and Characterization of	<u> </u>	etic Gene Cluster from		
	Sorangium Cellulosum" Gene, 249(1-2): 153-1	60, 2000.	Cl 11 2017		
	*Kalesse, et al., "The Formal Total Synthesis of	f Epothilone A" Eur. J. Or	g. Chem., 11: 281/-		
	2823, 1999. *Klar, et al., "Epothilones" Book of Abstracts,	219th ACS National Meeting	ng San Francisco, CA.		
	March 26-30, ORGN-288, 2000.	219 7100 Hadional Mood	,		
	*Koch, et al., Diastereoselective Titanium Eno	ate Aldol Reaction for the	Total Synthesis of		
	Epothilones Organic Letters, 2(22): 3811-3814	, 2002.			
	*Krische, et al., "Diastereoselective Cobalt-Car	alyzed Aldol and Michael	Cycloreductions" J. Am.		
	Chem. Soc. 123: 5112-5113, 2001. *Lee, et al., "BMS-247550: A Novel Epothilo	na Analog with a Mode of	Action Similar to		
!	Paclitaxel but Possessing Superior Antitumor I				
	*Lee, et al., "Synthesis of the C11-C21 and C1	3-C21 Fragments of Epoth	ilones from D-glucose"		
	Bull. Korean Chem. Soc., 21(12): 1177-1178, 2	000.			
	*Lee, et al., "Synthesis Toward Epothilone A:	A Coupling Reaction Betv	veen the Sulfone of C1-		
	C10 and the Allylic Bromide of C11-C21" Bull. Korean Chem. Soc., 20(4): 403-404, 1999.				
	*Lee, et al., "Insights into Long-Range Structural Effects on the Stereochemistry of Aldol				
	Condensations: A Practical Total Synthesis of Deoxyepothilone F" J. Am. Chem. Soc. 123: 5249-259, 2001.				
	Lee, et al., "Total Synthesis and Antitumor Activity of 12,13-Desoxyepothilone F: An				
	Unexpected Solvolysis Problem at C15, Mediated by Remote Substitution at C21" J. Org. Chem.,				
	65 : 6525-6533, 2000.				
	*Li, et al., "Synthesis of a Novel Epothilone B Analog as a Potential Photoaffinity Label" Abstr.				
	PapAm. Chem. Soc. 221 st , MEDI-137, 2001 *Li, et al., "Process Development of the Semisynthesis of a Biologically Active Epothilone				
{	Analogue"	ynthesis of a Diologically 7	tenve Eponmone		
	Abstracts of Papers, 222 nd ACS National Meets	ng, Chicago, IL, August 20	6-30, ORGN-238, 2001.		
	*Li, et al., "Antimitotic Agents" Annu. Rep. M.	ed. Chem., 34: 139-148, 19	99,		
	*Lichtner, et al., "Subcellular Distribution of E	pothilones in Human Tum	or Cells" Proc. Natl.		
	Acad. Sci. U.S.A., 98(20): 11743-11748, 2001.				
	*Lin, et al., "Design, Synthesis and SAR of No	vel Hybrid Constructs Bas	ed on the Common		
	Pharmacophore for Microtubule-Stabilizing Ag		17" ACS Nanonai		
meeting, Anaheim, CA, March 21-25, MEDI-038, 1999. *Lin, et al., "Design and Synthesis of Taxoid-Epothilone Hybrids" Book of Abstracts, 216th			of Abstracts, 216th ACS		
	National Meeting, Boston, August 23-27, ORG				
√p	*List, et al., "Proline-Catalyzed Direct Asymm	etric Aldol Reactions" J. A	Am. Chem. Soc. 122:		
7'0	2395-2396, 2000.				
	*Liu, et al., Total Synthesi of Epothilone A thr	ough Stereospecific Enoxid	dation of the p-		
	Methoxybenzyl Ether of Epothilone C Chem. E				
	*Liu, et al., "Epoxide Opening with Acetylide				
	<u> </u>				

FORM PTO	U.S. Department of Comm	nerce ATTY. DOCKET:	IN RE			
(REV. 8-83)	Patent and Trademark Off	ice 2003080-0143	APPLICATION NO.:			
		(SK-744-CON9)	10/726,386			
	TION DISCLOSURE STATEMENT	APPLICANT: Danis	shefsky <i>et al</i>			
(Use	several sheets if necessary)	FILING DATE:	GROUP:			
		December 2, 2003				
-10	Tetrahedron Lett. 39(29): 5261-5264, 1998.					
	*Liu, et al., "Synthesis of the C11-16+C27 Segment of Epothilone A", Chin. Chem. Lett.9(1): 35-38, 1998.					
	*Machajewski, et al., "Chemoenzymic Sy Iss.), 1469-1472, 1999.					
	*Martin, et al., Marshall, "Total Synthesis	of Epothilone", Nat. Biotec	hnol. 15 (3): 205, 1997.			
	*Martin, et al "The 12,13-diol Cyclization of Epothilone B and the Synthesis of a Conchem. Eur. J, 42(47): 8373-8377, 2001	nformationally Restrained A	nalog"			
	*Martin, "How Stable are Epoxides? A N ,39(3): 581-583, 2000.					
	*May, et al., "Total Synthesis of (-) Epothilone B", Chem. Commun., 95: 1369-1374, 1998.					
	*McDaid, et al., Validation of the Pharmacodynamics of BMS-247550, an Analogue of Epothilone B, During a Phase I Clinical Study, <i>Clinical Cancer Research</i> , 8: 2035-2043, 2002.					
	*Meng, Dongfang, et al., "Chapter I: The First Total Syntheses of Epothilones A, B, C and D. Chapter II: The First Total Syntheses of 12-epi-CP-263,114 and 12-epi-CP-225,917" Columbia University					
	Order No.: DA9949022 From: Diss. Abstr. Int., B2000, 60(10), 5096 (1999)					
	*Molnar, et al., "The Biosynthetic Gene Cluster for the Microtubule-Stabilizing Agents					
	Epothilones A and B from Sorangium Cellulosum So ce90" Chem. Biol., 7(2): 97-109, 2000. *Mulzer, et al., "Epothilone B and its Derivatives as Novel Antitumor Drugs: Total and Partial					
	Synthesis and Biological Evaluation" Mon					
	*Mulzer, et al., "Total Syntheses of Epothilones B and D" J. Org. Chem., 65(22); 7456-7467, 2000.					
	*Mulzer, et al., "A Novel Highly Stereoselective Total Synthesis of Epothilone B and of its (12R,13R) Acetonide" <i>Tetrahedron Lett</i> , 41(40): 7635-7638, 2000					
	*Mulzer, et al., "Synthesis of the C(11)-C(20) Segment of the Cytotoxic Macrolide Epothilone B", Tetrahedron Letters", 38(44): 7725-7728, 1997.					
	*Mulzer, et al "Easy Access to the Epothilone Family-Synthesis of Epothilone B", Tetrahedron Letters, 39(47): 8633-8636, 1998.					
	*Mulzer, "Progress in the Synthesis of Chiral Heterocyclic Natural Products: Epothilone B and Tartrolon B" J. Heterocycl. Chem., 36(6): 1421-1436, 1999.					
	*Nakamura, S., "Total Synthesis of Antitumor Antibiotic Epothilone Having Same Mechanism of Action with Taxol", Kagaku (Kyoto)", (In Japanese) 52(7): 70-71, 1997.					
,	*Newman, et al., "Antitumor Efficacy of 26-Fluoroepothilone B Against Human Prostate Cancer Xenografts" Cancer Chemother. Pharmacol., 48(4): 319-326, 2001.					
	*Nicolaou, et al., Recent Developments in Epothilones		l Medicine of the			
	Chem. Commun., 1523-1535, 2001.					
	*Nicolaou, et al., "Synthesis and Biologic cyclobutyl Epothilones"	al Evaluation of 12, 13-cycle	opropyl and 12,13-			
N/	ChemBioChem (Angew. Chem. Int. Ed. E.	ngl.), 2 (1): 69-75, 2001.				

FORM PT	O-1449	U.S. Department of Commerce	ATTY. DOCKET:	IN RE			
(REV. 8-83)		Patent and Trademark Office	2003080-0143	APPLICATION NO.:			
			(SK-744-CON9)	10/726,386			
		LOSURE STATEMENT	APPLICANT: Danishefsky et al				
(Use	several shee	ts if necessary)	FILING DATE:	GROUP:			
			December 2, 2003				
YD		, et al., "Recent Developments in the		Medicine of the			
10		es"Chem. Commun., 17: 1523-1535, 2 , et al "Chemical Synthesis and Biol		and trans 12.13			
	cycloprop	yl and 12,13-cyclobutyl Epothilones a	nd Related Pyridine Side	Chain Analogues" L Am			
		:, 123(38): 9313-9323, 2001.	and Itolated I filanie State	Onem: . m.m.ogo			
	*Nicolaou	, et al., "Synthesis of 16-desmethylepe	othilone B: Improved Me	ethodology for the Rapid,			
	Highly Se 519-520, 1	lective and Convergent Construction (of Epothilone B and Analo	ogs" Chem. Commun., 6:			
		, et al., "Total Synthesis of 16-Desme					
}	F .	ed Side Chain Modified Epothilone B	Analogues", Chem. Eur.	J., 6 (15): 2783-2800,			
		2000. *Nicolaou, et al., "Chemical Synthesis and Biological Properties of Pyridine Epothilones" Chem.					
		, et al., "Chemical Synthesis and Bioli 593-599, 2000.	ogical Froperties of Fyrid	inc Epointones Chem.			
		, et al., "Chemistry, Biology and Med	icine of Selected Tubulin	Polymerizing Agents"			
İ	Pure Appl	Pure Appl. Chem., 71(6): 989-997, 1999.					
	*Nicolaou, K.C. et al. "Synthesis and Biological Properties of C12,13-Cyclopropyl-Epothilone A						
	and Related Epothilones" Chem. Biol, 5(7): 365-372, 1998.						
	*Nicolaou, et al., "Total Synthesis of Epothilone E and Related Side-Chain Modified Analogues						
	via a Stille Coupling Based Strategy" Bioorg. Med. Chem., 7(5): 665-697, 1999. *Nicolaou, et al., Chemie und Biologie der Epothilone, Agnew. Chem., 110: 2120-2153, 1998.						
	*Nicolaou, et al., "Probing the Ring Size of Epothilone: Total Synthesis of [14]-, [15]-,[17]-,"						
ļ	Angew. Chem. Int. Ed. 37: 81-87, 1998						
	*Nicolaou	*Nicolaou, et al., "Total Synthesis of Epothilone E and Analogues with Modified Side Chains					
	through th	through the Stille Coupling Reaction" Angew. Chem. Int. Ed., 110: 85-92, 1998.					
	*Nicolaou, et al., Intellectual Screening of Natural Products for Drugs", Farumashia, 33(12):						
	1339-1345, 1997. *Nicolaou, K.C. et al., "Total Synthesis of 26-hydroxyepothilone B and related analogues", Chem.						
	Commun. 2343-2344 (1997)						
		*Nicolaou, et al., "Chemical Biology of Epothilones", Angew. Chem. Int. Ed., 37: 2014-2045,					
	1998.	1998.					
	*Nicolaou	*Nicolaou, et al., "Ring-Closing Metathesis in the Synthesis of Epothilones and Polyether Natural Products" Top. Organomet. Chem. 1 (Alkene Metathesis in Organic Synthesis)1: 73-104, 1998.					
	Products"	Top. Organomet. Chem. 1 (Alkene Me, , et al., "The Olefin Methathesis Appr	elainesis in Urganic Synif	lite Analoge" 1 Am			
		, et al., "The Oleffin Methathesis Appr c. <i>Doc.</i> 119 (34): 7960-7973, 1997.	oach to Epoumone A and	i ita Alialoga , J. Alli.			
	*Nicolaou	, et al., Synthesis of Epothilones: A ar	nd B in Solid and Solution	n Phase", Nature, 387:			
	268-272, 1	997.					
		*Nicolaou, et al., "Synthesis of Epothilones: A and B in Solid and Solution Phase", Nature, 390:					
	*Njaardars	son, et al., Application of hitherto une					
	epothilone	series: novel epothilone analogs by to	otal synthesis, Chem. Con	nmun., 2759-2761, 2002.			
		al., 'New-Generation Taxoids and H					
$\backslash \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \! \!$	_	ook of Abstracts, 219 th ACS National	Meeting, San Francisco,	CA, March 20-30,			
V	ORGN-24	J, 2000.					

FORM PTO-	1449 U.S. Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)	Patent and Trademark Office	2003080-0143	APPLICATION NO.:	
(REV. 6-63)	Tatent and Trademark Office	(SK-744-CON9)	10/726,386	
INFORMAT	ION DISCLOSURE STATEMENT	(311 1 1 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		
1		APPLICANT: Danishef	T	
(Use s	everal sheets if necessary)	FILING DATE:	GROUP:	
		December 2, 2003		
40	*Ojima, et al., "A Common Pharamcophore for		ts that Stabilize	
1-1-	*Panicker, et al An unusual Reversal of Stere		listed Aldol Reaction	
	Enantioselective Synthesis of the C1-C6 Segm	ent of the Enothilones" Tet	rahedron, 56 (40): 7859-	
	7868, 2000.	one of the Epotimones Tol	(4,104, 51, 50((6), 7 555	
	*Petrache, et al., "The Role of the Microtubule	s in Tumor Necrosis Factor	r-a-Induced Endothelial	
	Cell Permeability" Am. J. Respir. Cell Mol. Biol.,	28 : 574-581, 2003.		
	*Pradella, et al Characterisation, Genome Size		of the Myxobacterium	
	Sorangium Cellulosum So ce56, Archives of M	icrobiology, 1-17, 2002.	' 1' 41 - M '110'	
	*Pryor, et al., The Microtubule Stabilizing Age	nt Laulimalide Does Not B	ing in the Taxoid Site,	
.	Kills Cells Resistant to Paclitaxel and Epothilo Activity <i>Biochemistry</i> , 41: 9109-9115, 2002.	iics, and iviay ivot Require	no Epoxide Moiety 101	
 	*Quitschalle, et al., "Improved Synthesis of the	Northern Hemisphere of I	Epothilone A by a	
	Sharpless Asymmetric Dihydroxylation" <i>Tetra</i>	hedron Letters., 40 (44): 77	65-7768, 1999.	
	*Regentin, et al., "Development of a Cost Effective Epothilone D Process in Myxococcus			
	Xanthus" Abstr. Pap-Am. Chem. Soc. 221st, BIG	<i>OT-061</i> , 2001.		
	*Regentin, et al., Nutrient Regulation of Epoth	lone Biosynthesis in Heter	ologous and Native	
	Production Strains Appl Microbiol Biotechnol,	61: 451-455, 2003.	·1	
	*Regueiro-Ren, et al., "Synthesis and Biologic	al Activity of Novel Epothi	lione Aziridines" <i>Org</i> .	
 	Lett., 3(17): 2693-2696, 2001. *Regueiro-Ren, et al., SAR and pH Stability of	Cyano-Substituted Enothi	lones Organic Letters	
\ \ \ \	4(22): 3815-3818, 2002.	Cyano-Substituted Epotin	ionos, organic Beners,	
	*Reiff, et al., "Progress Toward Total Synthese	s of Epothilones A and B"	Book of Abstracts, 215th	
	-ACS National Meeting, Dallas, March 29-Apri	<i>I-2, ORGN-086 </i> ₩>	10ar	
10	*Rivkin, et al., Complex Target-Oriented Total	Synthesis in the Drug Disc	covery Process: The	
70	Discovery of a Highly Promising Family of Se	cond Generation Epothilon	es, J. Am. Chem. Soc,	
-	125: 2899-2901, 2003.	23 TO -1	an Divin a Conside Ping	
}	*Rivkin, et al., Total Syntheses of [17]- and [1] Closing Metathesis-Based Strategy: Correlation	of Ping Size with Biological	ical Activity in the	
	Epothilone Series J. Org. Chem., 67: 7737-774		ical Activity in the	
	*Rivkin, et al., On the Introduction of a Triflu	oromethyl Substituent in th	e Epothilone Setting:	
	Chemical Issues Related to Ring Forming Olef	in Metathesis and Earliest	Biological Findings	
	Organic Letters, 4(23): 4081-4084, 2002.			
	*Santi, et al., "An Approach for Obtaining Per	fect Hybridization Probes f	or Unknown Polyketide	
	Synthase Genes: A Search for the Epothilone	Jene Cluster" Gene, 247(1	-2): 9/-102, 2000.	
	*Sawada, et al., "Enantioselective Total Synthe Asymmetric Catalysis" Angew. Chem. Int. Ed.,		IVIUITIUIICUOIIAI	
 	*Sawada, et al., "Enantioselective Total Synthe	esis of Epothilones A and F	3 Using Multifunctional	
1/	Asymmetric Catalysis" J. Am. Chem. Soc., 122	(43): 10521-10532, 2000.		
Incompleter		Complexes of Molybdenur	n and Tungsten.	
-	*Sefkow, et al., "Derivatization of the C12-C1			
70	Bioorg. Med. Chem., 8: 3031-3036, 1998.			

FORM PTO	-1449 U.S. Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)	Patent and Trademark Office	2003080-0143 APPLICATION NO.		
(KE V. 0-03)	Falent and Trademark Office	(SK-744-CON9)	10/726,386	
INFORMAT	TION DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al		
_	several sheets if necessary)		, 	
(036.3	everus success y necessury)	FILING DATE:	GROUP:	
		December 2, 2003		
4,0	*Sefkow, et al., "Oxidative and Reductive Trans Chem.8(21): 3025-3030, 1998.			
	*Sefkow, et al., "Substitutions at the Thiazole M 2488, 1998.			
	*Schinzer, et al., "Total Synthesis of (-)-epothilo			
	*Schinzer, et al., "Total Synthesis of (-)-epothile	one B" ChemEur. J., 5(9)): 2492-2500, 1999.	
	*Schinzer, et al "Synthesis and Biological Eval Ed. ChemBiochem, 1(1): 67-70, 2000.			
1	*Schinzer, et al., "Synthesis of Epothilones. Ster 861-864, 1998.			
	*Schinzer, Interview: Epothilones-New Promis		ng Products with Taxol-	
	like Biological Activity, ECC Braunschewig	In Complete	4 3 ova 5 (tert	
40	*Schinzer, et al., "New and Convenient Synthes butyldiphenylsilyloxy)methylpentanoate and 2-r		/1-3-0xa-3-(1611-	
	butyldimethylsiloxy)methylpentanoate" <i>Phosph</i>	orus. Sulfur Silicon Relat.	Elem., 158: 187-199,	
1	2000.			
	*Schneider, et al., Utilzation of Alternate Substr	ates by the First Three Mo	odules of the Epothilone	
	Synthetase Assembly Line J. Am. Chem. Soc., 12	24: 11272-11273, 2002.	7 101 5	
	*Scholl, et al., "Increased Ring Closing Metathe	esis Activity of Ruthenium	-Based Oletin	
	Metathesis Catalysts Coordinated with Imidazol 1999.	in-2-Yildene Ligands Tel	tranearon Lett. 40. 2247,	
	*Scudiero, et al., Evaluation of a Soluble Tetraz	olium/Formazan Assay fo	r Cell Growth and Drug	
	Sensitivity in Culture Using Human and Other 1 4833, 1988.	Tumor Cell Lines, Cancer	Research, 48 : 4827-	
	*Shibasaki, et al., "Multifunctional Asymmetric 2001.			
	*Shioji, et al., "Synthesis of C1-C6 Fragment for Resolution" Synth. Commun., 31(23): 3569-357	5, 2001.		
	*Sinha, et al., "The Antibody Catalysis Route to Acad. Sci95(25): 14603-14608, 1998.	the Total Synthesis of Ep		
V	*Sinha, et al., "Catalytic Antibody Route to the of Epothilones A-F" Chem. Eur. J.,7(8): 1691-1	702, 2001.		
	*Sinha, et al "Total Synthesis of Epothilones a	nd Some 14-Flouroanalog	s via Antibody	
	Catalysis"———————————————————————————————————	Anaham CA March 21	25 ORGN-054	
	*Sinha, et al., "Synthesis of Epothilone Analogu	ies by Antibody-Catalyze	1 Resolution of Thiazole	
70	Aldol Synthons on a Multigram Scale. Biologic Epothilones" ChemBioChem, 2(9): 656-665, 20	cal Consequences of C-13	Alkylation of	
	*Sinha, et al., "Sets of Aldolase Antibodies with	n Antipodal Reactivities.	Formal Synthesis of	
	Epothilone E by Large Scale Antibody-Catalyze 1623-1626, 1999.	ed Resolution of Thiazole	Aldol" Org. Lett., 1(10):	
	*Sinha, et al., "Regioselective Synthesis of Fluo	oro Aldols. Studies Towar	d Fluro Epothilones	

FORM PTO	-1449	U.S. Department of Commerce	ATTY. DOCKET:	IN RE	
(REV. 8-83)		Patent and Trademark Office	2003080-0143	APPLICATION NO.:	
			(SK-744-CON9)	10/726,386	
INFORMAT	TION DISCLOS	URE STATEMENT	APPLICANT: Danishefsky et al		
(Use :	several sheets if n	ecessary)	FILING DATE:	GROUP:	
			December 2, 2003		
70	Syntheses via A	ntibody Catalysis" Tetrahedron		6, 2000.	
1		New Colorimetric Cytotoxicity			
		ncer Institute, 82 : 1107-1112, 1			
*Smart, Fluorine Substituent Effects (on bioactivity) Journal of Fluorine Chemistry, 109: 3-2001.					
		"The Epothilones, Eleutherobin	s, and Related Types of M	olecules" Curr. Pharm.	
	Des., 7(13): 127	7-1290, 2001. "Chemo- and Stereoselective E	navidation of 12 12 Decay	venothilone Pusing	
İ		oxirane" Tetrahedron Lett., 42(yeponinone is using	
		ereoselective Synthesis of 1,3-L		cation to the Ansa Bridge	
		J. Am. Chem. Soc. 105: 2487-2			
		ture - Activity Relationships o		irst In Vivo Comparison	
		Angew. Chem. Int. Ed. Engl.36:		line of Chienard	
\	*Tamao, et al., "Selective Carbon-Carbon Bond Formation by Cross-Coupling of Grignard Reagents with Organic Halides. Catalysis by Nickel-Phospine Complexes" J. Am. Chem St. 4374-4379, 1972.			" I Am Chem Soc 94:	
1				J. Am. Chem 800. 74.	
		loning and Expression of the E	pothilone Gene Cluster" So	cience, 287 : 640-642,	
	2000.	•			
		eneration of Novel Epothilone		ctivity by	
		on The Journal of Antibiotics, 5		Comment of Enothilones"	
		., "Simple Synthesis of Both Er ol. Biochem, 62(12): 2428-2430		segment of Epotimones	
	· ·	., "Easy Access to Both Enanti 1): 4353-4360, 1999.	omers of C7-C12 Segment	of Epothilones" Synth.	
1		Total Synthesis of Epothilones	B and D" Org. Lett., 3(14)	: 2221-2224, 2001.	
	*Taylor et al. "	The Identification of the Biolog	cically Active Conformation	on of Epothilone"	
No Year		ts, 217th ACS National Meeting			
40	5449, 2000.	The Conformational Properties			
	1999.	Conformational Properties of E			
		Catalytic Diastereoselective Rec			
Interdependent Reaction Variables by Arrayed 12202-12203, 1999. *Taylor "A Formal Total Synthesis of Epothilo and C7-C12 Fragments" J. Org. Chem., 63(25)					
		9580-9583, 1998.			
*Ter Haar, et al., "Taxanes and Other 8(5): 571-586, 1998.			ule Stabilizing Agents" Ex	pert. Opin. Ther. Pat.,	
	*Trnka, et al., "The Development of L ₂ X ₂ Ru=CHR Olefin Metathesis Catalysts: An				
		Success Story", Acc. Chem. Re		alizatar Am	
		he Development of L2X2Ru=C Success Story Acc. Chem.Res.,		arysts: An	
V	Organometathe	Success Story Acc. Chem. Res.,	34. 10-47, 4001.		

FORM PTO	-1449	U.S. Department of Commerce	ATTY. DOCKET:	IN RE
(REV. 8-83)		Patent and Trademark Office	2003080-0143	APPLICATION NO.:
			(SK-744-CON9)	10/726,386
		OSURE STATEMENT	APPLICANT: Danishef	sky et al
(Use s	several sheet:	s if necessary)	FILING DATE:	GROUP:
			December 2, 2003	
40	*Valluri, et	al., "Total Synthesis of Epothilone l	B" Org. Lett., 3(23): 3607-	3609, 2001.
	*Victory, et al., "Development of an Epothilone Pharmacophore" Book of Abstracts, 215th ACS			
		eeting, Dallas, March 29-April 2. M		
40		, "Epothilones A and B: Springboar	ds for Semisynthesis of Pr	romising Antimitotic
1,0	Agents"	stracts, 219 th ACS National Meeting,	Sau Francisco CA Mare	A 26 20 OPCN 286
	<i>Book of Ab</i> . 2000.	stracts, 219 ACS National Meeting,	San Francisco, CA, Marc	n 20-30, OKON-200,
		rer, E"Tubulin as a Target for Antic	ancer Drugs" Curr. Opin.	Drug Discovery Dev.,
	3(5): 575-5	84, 2000.		
	*Walsh, C.	"Enzymatic Assembly of Hybrid Po	lyketide/Nonribosomal Pe	ptide Natural Products"
		f Papers, 222 nd ACS National Meetir		
1		nn, et al., "Synthesis of Natural-Prod	uct-Based Compound Libi	raries" Curr. Opin.
	Chem. Biol	n, 4: 303-309, 2000. nn, et al. "Synthetic Access to Epothi	lance Matural Products with	th Extraordinary
	Anticancer	n, et al. Synthetic Access to Epoth Activity" Org. Synth. Highlights IV	Fd. Schmalz H Wiley-V	CH Verlah GmhH:
∮ '		Germany, 251-267, 2000	Du. Denmail, 11., 11 tiey 7	CII / C/ WG Cimoii
	*White, et	al., Total Synthesis of Epothilone B,	Epothilone D and cis-and	trans-9, 10-
	Dehydroep	othilone D, J. Am. Chem. Soc., 125: 3	3190, 2003.	
		otal Synthesis of Epothilone B, Epoth		s-9,10-
	Dehydroep	othilone D" J. Am. Chem. Soc., 123(23): 5407-5413, 2001.	ilono D" Pook of
	Abstracts	al., "Synthetic Approach Towards the ALS" ACS National Meeting, Boston,	e Total Symmesis of Epoin August 23-27 ORGN-041	No YOR
~(.	*White et	al "Two Coupling Strategies for a S	Stereoselective Synthesis o	f Epothilone B" Book of
70	*White, et al., "Two Coupling Strategies for a Stereoselective Synthesis of Epothilone B" Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, ORGN-813, 2000.			
	*White, et al., "A Highly Stereoselective Synthesis of Epothilone B" J. Org. Chem., 64(3): 684-			
	685, 1998.			
		al., "Improved Synthesis of Epothilo		n of an Alkyne for
	*Winkler	of Subunits" Org. Lett., 1(9): 1431-14 et al., "A Model for the Taxol (Paclit	434, 1999. avel) Enothilone Pharmace	onhore" Rigara Med
		et al., 'A Model for the Taxof (Facility). Er, 6 : 2963-2966, 1996.	axer, prominent manifact	opiloto , Dioor 5., mou.
		et al., "Design and Synthesis of Cons	trained Epothilone Analog	gs: The Efficient
	Synthesis of	f Eleven-Membered Rings by Olefir	Metathesis" Tetrahedron	, 55(27): 8199-8214,
	1999.			·
	*Winssinge	er, et al., "Epothilones and Sarcodict	yins: From Combinatorial	Libraries to Designed
	_	ook of Abstracts, 219th ACS National	u Meeting, San Francisco,	CA, IVIAICH 20-3U,
	•Wittmann	, 2000. , et al., Flavopiridol Down-Regulate	s Antiapoptotic Proteins ar	nd Sensitizes Human
	Breast Can	cer Cells to Epothilone B-induced A	poptosis, Cancer Research	h, 63 : 93-99, 2003.
	*Wolff, A.	"Epothilone A Induces Apoptosis in	n Neuroblastoma Cells wit	h Multiple Mechanisms
	of Drug Re	sistance", Int. J. Oncol., 11(1): 123-	126, 1997.	
	*Woltering	, et al., Development of a Novel In \	/itro Human Tissue-Based	Angiogenesis Assay to
	Evaluate th	e Effect of Antiangiogenic Drugs, A	nnals of Surgery, 237 : 790)-800, 2003.

FORM PTO- (REV. 8-83)	-1449 U.S. Department of Comme Patent and Trademark Office	•	IN RE APPLICATION NO.: 10/726,386
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishe	fsky <i>et al</i>
(Use s	everal sheets if necessary)	FILING DATE: December 2, 2003	GROUP:
40	*Yang, et al., "Total Synthesis of Epothilone Int. Ed., 36: 166-168, 1997.		
	*Yoshimura, et al., Synthesis ad Conformational Analysis of (E)-9, 10-Dehydroepothilone B: A Suggestive Link between the Chemistry and Biology of Epothilones, Angew. Chem. Int. Ed. 42 2518-2521, 2003.		
	*Zhou, et al., Brominated Derivatives of No That Perturb Mitosis and Inhibit Cell Prolife	eration, Molecular Pharmacol	ogy, 63 : 799-807, 2003.
$\sqrt{}$	*Zhu, et al., "Methodology Based on Chiral Natural Products-Total Synthesis of Epothil	one A" Eur. J. Org. Chem., 9	: 1701-1714, 2001.
-	*Zhu, et al., "Studies Toward the Total Synt National Meeting, Boston, August 23-27, Oi	RGN-660 No Yeb	W
70	*Zhu, et al "Enzymatic Resolution of Thia C12-C21 Fragment of the Epothilones" <i>Tetr</i>	rahedron Lett., 41(12): 1863-	1866, 2000.
	*Zhu, et al "Studies Toward the Total Synthesis of Epothilone A" Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, ORGN-060, 2000.		
\overline{V}	*Zhu, et al., "Total Synthesis of Epothilone A" Org. Lett., 2(17): 2575-2578, 2000.		
EXAMINER	T. A. Solol	a DATE CONSIDI	ERED 8-18-05

through citation if not in conformance and not considered. Include copy of this form with next communication to

3671140

applicant.

FORM PTO-1 (REV. 8-83)	Comn	Department of nerce and Trademark Office	ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLIC NO.: 10/726,3	
INFORMATI	OPCULSCE SURE	STATEMENT	APPLICANT: Danishefsky et al		
	veral sheets if necessor		FILING DATE:	GROUP	·
(Ose severus shoots by housessury)		DECEMBER 2, 2003			
			DECEMBER 2, 2000		
U.S. PATENT	DOCUMENTS				1
Examiner's	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
Initials					
40	5,021,430	Ksander, et al.	June 4, 1991	514	332
	5,917,084	Jiang, et al.	June 29, 1999	560	174
	5,969,145	Schinzer, et al.	October 19, 1999	548	110
	6,043,372	Schinzer, et al.	March 28, 2000	548	110
	6,156,905	Schinzer et al.	December 5, 2000	548	204
	6,262,094	Höfle, et al.	July 17, 2001	514	365
	6,284,781	Danishefsky, et al.	September 4, 2001	514	365
	6,288,237	Höfle, et al.	September 11, 2001	548	203
	6,291,684	Borzilleri, et al.	September 18, 2001	548	961
	6,302,838	O'Reilly et al	October 16, 2001	574	365
	6,303,342	Julien	October 16, 2001	435	76
	6,303,767	Betlach	October 16, 2001	536	23.2
	6,320,045	Kim, et al.	November 20, 2001	540	463
	6,350,878	Altmann, et al.	February 26, 2002	548	110
	6,359,140	Höfle, et al.	March 19, 2002	548	204
	6,365,749	Kim et al.	April 2, 2002	548	204
	6,380,227	Mutz	April 30, 2002	514	365
	6,380,394	Nicolaou	April 20, 2002	548	125
	6,380,395	Vite	April 30, 2002	548	146
	6,383,787	Schupp	May 7, 2002	435	183
	6,384,230	Mulzer	May 7, 2002	548	203
· \ \	6,387,927	Altmann	May 14, 2002	514	311
	6,399,638	Vite	June 4, 2002	514	366
	6,410,301	Julien	June 25, 2002	435	252.3
	6,419,692	Yang et al.	July 16, 2002	623	115
	6,441,186	Nicolaou et al.	August 27, 2002	548	204
	6,457,303	Georg et al.	October 1, 2002	56	465
	6,515,017	Li et al.	February 4, 2003	514	449
	6,518,421	Li et al.	February 11, 2003	540	462
	6,525,197	Furstner et al.	February 25, 2003	544	310
	6,531,497	Nicolaou et al.	March 11, 2003	514	370

FORM PTO-	1449 U.S. E Comm	Department of nerce	ATTY. DOCKET: 2003080-0143	IN RE APPLIC	ATION
(REV. 8-83) Patent an		and Trademark Office	(SK-744-CON9)	NO.: 10/726,386	
INFORMAT	ION DISCLOSURE S	STATEMENT	APPLICANT: Danishefsky et al		
(Use s	everal sheets if necessa	ıry)	FILING DATE:	GROUP:	:
		DECEMBER 2, 2003			
70	6,537,988	Lee	March 25, 2003	514	221
	6,538,038	Pero et al.	March 25, 2003	514	731
	6,544,544	Hunter et al.	April 8, 2003	424	424
	6,576,651	Bandyopadhyay et al.	June 10, 2003	514	365
	6,593,115	Vite et al.	July 15, 2003	435	134
	6,596,875	White et al.	July 22, 2003	548	204
	6,603,015	Georg et al.	August 5, 2003	548	203
	6,603,023	Danishefsky et al.	August 5, 2003	549	346
	6,605,599	Vite et al.	August 12, 2003	514	63
	6,605,726	Mulzer et al.	August 12, 2003	548	202
	6,610,736	Klar et al.	August 26, 2003	514	450
	6,613,912	Hoefle et al.	September 2, 2003	548	204
	6,624,310	Hoefle et al.	September 23, 2003	548	204
	6,625,666	O'Reilly et al.	October 21, 2003	710	5
	6,686,380	Lee	February 3, 2004	514	365
	6,689,802	DiMarco et al.	February 10, 2004	514	365
Ì	6,719,540	Regueiro-Ren et al.	April 13, 2004	417	365
	6,723,854	Danishefsky et al.	April 20, 2004	548	203
	6,727,276	Lee	April 27, 2004	514	540
	6,730,699	Li et al.	May 4, 2004	514	449
	6,730,803	Iwasaki et al.	May 4, 2004	558	442
	6,780,620	Li et al.	August 24, 2004	435	117
	6,800,653	Regueiro-Ren et al.	October 5, 2004	514	365
u.s. paten	r applications				
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:
70	2001/0031880	Borzilleri et al.	October 18, 2001		
	2001/0034452	Hoefle et al.	April 16, 2001		
	2001/0051356	Khosla	December 13, 2001		
V	2002/0002162	Lee	January 3, 2002		

FORM PTO-14 (REV. 8-83)	Comm	Department of nerce and Trademark Office	ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLICATION NO.: 10/726,386
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefs		
	veral sheets if necessor		FILING DATE: GROUP: DECEMBER 2, 2003	
40	2002/0004229	Santi et al.	January 10, 2002	
	2002/0010328	Reeves et al.	January 24, 2002	
	2002/0028839	O'Reilly et al.	March 7, 2002	
	2002/0042109	Vite et al.	April 11, 2002	
	2002/0045220	Khosla et al.	April 18, 2002	
	2002/0045609	Ashley et al.	April 18, 2002	
	2002/0052028	Santi et al.	May 2, 2002	
	2002/0058286	Danishefsky et al.	May 16, 2002	
	2002/0058817	Danishefsky et al.	May 16, 2002	
	2002/0062030	White et al.	May 23, 2002	
	2002/0065295	Chu et al.	May 30, 2002	
	2002/0143026	Lombardo et al.	October 3, 2002	
	2002/0143038	Bandyopadhyay et al.	October 3, 2002	
	2003/0203938	Nicolaou et al.	October 30, 2003	
	2003/0203929	Ghosh	October 30, 2003	
_	2003/0203876	Hoogevest	October 30, 2003	
	2003/0194787	Hofmann et al	October 16, 2003	
	2003/0191089	Regueiro-Ren et al.	October 9, 2003	
	2003/0187273	White et al.	October 2, 2003	
	2003/0187039	Favreau et al.	October 2, 2003	
	2003/0186983	Mastalerz et al.	October 2, 2003	
	2003/0186965	Vite et al.	October 2, 2003	
	2003/0180760	Basch et al.	September 25, 2003	
	2003/0176710	Klar et al.	September 18, 2003	
	2003/0176473	Taylor et al.	September 18, 2003	
	2003/0176368	Danishefsky et al.	September 18, 2003	
	2003/0176320	Li et al.	September 18, 2003	
	2003/0171596	Danishefsky et al.	September 11, 2003	
	2004/0023345	Vite et al.	February 5, 2004	
	2004/0024032	Voi et al.	February 5, 2004	

FORM PTO-14 (REV. 8-83)	Comr	Department of nerce t and Trademark Office	ATTY. DOCKET: 2003080-0143 (SK-744-CON9)	IN RE APPLICATION NO.:
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefsky et al		
	eral sheets if necess		FILING DATE: GROUP:	
(337337	,	,,	DECEMBER 2, 2003	
70	2004/0024033	O'Reilly et al.	February 5, 2004	
1	2004/0030147	White et al.	February 12, 2004	
	2004/0038324	Atadja et al.	February 26, 2004	
	2004/0039026	Nicolaou et al.	February 26, 2004	
	2004/0044203	Wittman et al.	March 4, 2004	
	2004/0044221	Danishefsky et al.	March 4, 2004	
	2004/0049051	Hoefle et al.	March 11, 2004	
	2004/0053910	Danishefsky et al.	March 18, 2004	
	2004/0053978	Lee et al.	March 18, 2004	
	2004/0053995	Danishefsky et al.	March 18, 2004	
	2004/0054186	Das et al.	March 18, 2004	
	2004/0054188	Kusters et al.	March 18, 2004	
	2004/0058899	Klimko	March 25, 2004	
	2004/0058969	Buchmann et al.	March 25, 2004	
	2004/0062810	Hunter et al.	April 1, 2004	
	2004/0063707	Bhide et al.	April 1, 2004	
	2004/0063708	Bhide et al.	April 1, 2004	
	2004/0063712	Salvati et al	April 1, 2004	
	2004/0063715	Paruch et al.	April 1, 2004	
	2004/0072760	Carboni et al.	April 15, 2004	
	2004/0072832	Bhide et al.	April 15, 2004	
	2004/0072835	Paruch et al.	April 15, 2004	
	2004/0072870	Nicolaou et al.	April 15, 2004	
	2004/0072882	Johnson et al.	April 15, 2004	
	2004/0076672	Hunter et al.	April 22, 2004	
	2004/0077696	Borzilleri et al.	April 22, 2004	
	2004/0082651	Wessjohann et al.	April 29, 2004	
	2004/0087610	Pardee et al.	May 6, 2004	
	2004/0087634	Hoefle et al.	May 6, 2004	
V	2004/0092478	Rothermel et al.	May 13, 2004	

FORM PTO-14		epartment of	ATTY. DOCKET:	IN RE APPLIC	A TION
(DELL 0.03)	Comm		2003080-0143	NO.:	ATION
(REV. 8-83)	Patent	and Trademark Office	(SK-744-CON9)	10/726,3	86
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Danishefs	ky et al		
(Use sev	eral sheets if necessa	<i>ry</i>)	FILING DATE:	GROUP	
•			DECEMBER 2, 2003	,	
40	2004/0092514	Velaparthi et al.	May 13, 2004		
	2004/0092560	Hoefle et al.	May 13, 2004		
	2004/0097516	Dwyer et al.	May 20, 2004		
	2004/0102451	Guzi et al.	May 27, 2004		
	2004/0102452	Guzi et al.	May 27, 2004		
	2004/0102495	Danishefsky et al.	May 27, 2004		
	2004/0106624	Guzi et al.	June 3, 2004		
	2004/0106985	Jang	June 3, 2004		
	2004/0116442	Guzi et al.	June 17, 2004		
	2004/0126379	Adolf et al.	July 1, 2004		
	2004/0127432	Nicolaou et al.	July 1, 2004		
	2004/0132146	Benigni et al.	July 8, 2004		
	2004/0133271	Jang	July 8, 2004		
	2004/0132692	Sherrill et al.	July 8, 2004		
	2004/0132736	Guzi et al.	July 8, 2004		
	2004/0132754	Brandt et al.	July 8, 2004		
	2004/0142931	Vite et al.	July 22, 2004		<u></u>
	2004/0142990	Hofmann et al.	July 22, 2004		
	2004/0152708	Li et al.	August 5, 2004		
	2004/0157897	DiMarco et al.	August 12, 2004		
	2004/0167083	Bosslet et al.	August 26, 2004		
	2004/0167097	Zhou et al.	August 26, 2004		
	2004/0176429	Li et al.	September 9, 2004		
\overline{V}	2004/0192621	Nihei et al.	September 30, 2004		
FOREIGN PA	FENT DOCUMENT	S			
Examiner's	Document No.	Country	Date	Translat	ion
Initials				Yes	No
Yn	DE 195 42 986.9	Germany	17 November 1995		
	DE 196 39 456.2	Germany	25 September 1996		

FORM PTO-1	Comm		ATTY. DOCKET: 2003080-0143	IN RE APPLICATION
(REV. 8-83)	Patent	and Trademark Office	(SK-744-CON9)	NO.: 10/726,386
INFORMATIO	ON DISCLOSURE	STATEMENT	APPLICANT: Danishefs	ky et al
(Use ser	veral sheets if necesso	ary)	FILING DATE:	GROUP:
		1	DECEMBER 2, 2003	
70	DE 196 45 361	Germany	30 April 1998	
	DE 196 45 362	Germany	30 April 1998	
	EP 1 440 973	Europe	July 28, 2004	
	EP 1 428 826	Europe .	June 16, 2004	
	EP 1 407 784	Europe	April 14, 2004	
	EP 1 386 922	Europe	February 4, 2004	
	EP 1 080 082	Europe	October 6, 2004	
	WO 04/087045	International	October 14, 2004	
	WO 04/085421	International	October 7, 2004	
	WO 04/080458	International	September 23, 2004	
	WO 04/063151	International	July 29, 2004	
	WO 04/061116	International	July 22, 2004	
	WO 04/056832	International	July 8, 2004	
	WO 04/054624	International	July 1, 2004	
	WO 04/054622	International	July 1, 2004	
	WO 04/054514	International	July 1, 2004	
	WO 04/052401	International	June 24, 2004	
	WO 04/052361	International	June 24, 2004	
	WO 04/052237	International	June 24, 2004	
	WO 04/050089	International	June 17, 2004	
	WO 04/050057	International	June 17, 2004	
	WO 04/048372	International	June 10, 2004	
	WO 04/043954	International	May 27, 2004	
	WO 04/043454	International	May 27, 2004	
	WO 04/043400	International	May 27, 2004	
	WO 04/043363	International	May 27, 2004	
	WO 04/035050	International	April 29, 2004	
	WO 04/032923	International	April 22, 2004	
	WO 04/032872	International	April 22, 2004	
\//	WO 04/032866	International	April 22, 2004	

ORM PTO-14	49 U.S. D Comm	epartment of nerce	ATTY. DOCKET: 2003080-0143	IN RE APPLICATION
REV. 8-83)	Patent	and Trademark Office	(SK-744-CON9)	NO.: 10/726,386
NFORMATIO	N DISCLOSURE S	STATEMENT	APPLICANT: Danishefs	ky et al
(Use seve	eral sheets if necessa	ry)	FILING DATE: DECEMBER 2, 2003	GROUP:
70	WO 04/030627	International	April 15, 2004	
	WO 04/030620	International	April 15, 2004	
	WO 04/028610	International	April 8, 2004	,
	WO 04/028582	International	April 8, 2004	
	WO 04/026877	International	April 1, 2004	
	WO 04/026872	International	April 1, 2004	
	WO 04/026867	International	April 1, 2004	
	WO 04/026310	International	April 1, 2004	
	WO 04/026229	International	April 1, 2004	·
	WO·04/024735	International	March 25, 2004	
	WO 04/022560	International	March 18, 2004	
	WO 04/022080	International	March 18, 2004	
	WO 04/022062	International	March 18, 2004	
	WO 04/018635	International	March 4, 2004	
	WO 04/016269	International	February 26, 2004	
	WO 04/012735	International	February 12, 2004	
	WO 04/007476	International	January 22, 2004	
	WO 03/096975	International	November 27, 2003	
	WO 03/057830	International	17 July 2003	
	WO 02/096281	International	December 5, 2004	
	WO 02/046196	International	13 June 2002	·
	WO 02/042432	International	30 May 2002	
	WO 02/032844	International	16 October 2001	
	WO 99/028324	International	10 June 1999	
	WO 99/003848	International poly	28 January 1999	
	WO 95/003035	International 4	2 February 1995	
	WO 93/010121	International	27 May 1993	

EODM DTO 14	IO IIC Desemble of	ATTY DOCKET.	IN RE	
FORM PTO-144	U.S. Department of Commerce	ATTY. DOCKET: 2003080-0143	APPLICATION	
(REV. 8-83)	Patent and Trademark Office		NO.:	
(KEV. 0-03)	Fatent and Trademark Office	(SK-744-CON9)	10/726,386	
INFORMATIO	N DISCLOSURE STATEMENT	APPLICANT: Danishefsky	y et al	
(Use sever	ral sheets if necessary)	FILING DATE:	GROUP:	
		DECEMBER 2, 2003		
4,0	Altmann et al., "Epothilone B and Its Anal- Rev. Med. Chem. 3:149, 2003.	ogs -A New Family of Antic	cancer Agents" Mini-	
	Baggiolini et al., "Stereocontrolled Total S		ycholecalciferol and	
	1α, 25-Dihydroxyergocalciferol" J. Org. C			
	Balog et al., "Stereoselective Syntheses and Desmethylepothilone A Series: Some Surp (1997).			
	Bijoy et al., "Synthetic Studies Directed To	owards Epothilone A " Tet. L	ett. 39 :209-212, 1998.	
	Bollag et al., "Epothilones, a New Class of 55:2325-2333, 1995.			
	Bollag <i>et al.</i> , "Epothilones: Novel Microtul 6 (7):867-873, 1997.			
	Chakraborty et al., "Radical-induced Open 104, 1998.	ing of Trisubstituted Epothil	ones" Tet. Lett. 39:101-	
	Chakravarty et al., "Taxoid and Non-Taxoi	d Inhibitors of Microtubule	Disassembly:	
	Molecular Modeling Approach to Eludicate Abstracts, 214th ACS National Meeting, L	ion of a Common Pharmacop as Vegas, NV, September 7-	ohore" Book of 11, MEDI-075.	
	American Chemical Society. Chou et al., "Quantitative Analysis of Dose	Effect Palationships The C	ombined Effects of	
	Multiple Drugs or Enzyme Inhibitors" Adv			
	Chou et al., "Design and Total Synthesis of	Synthesis of a Superior Family of Epothiolone Analogues, mors to a Nonrelapsable State" Angew. Chem. Int. Ed. Engl.		
	Ermolenko et al., "Synthesis of Epothilone 2898, 2002.	<u></u>		
	Fletcher et al., "Structure of the Mitogen-Inducible TIS10 Gene and Demonstration That the TIS10-Encoded Protein Is a Functional Prostaglandin G/H Synthase" J. Biol. Chem. 267:4338-4344, 1992.			
	Giannakakou et al., "Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins" J. Biol. Chem. 272(27):17118-17125, 1997.			
	Haar, et al., "Discodermolide, A Cytotoxic Potently Than Taxol", Biochemistry, 35: 24	43-250, 1996.		
	Harris, et al., "Chemical Synthesis and Bio Stabilizing Agents with Enhanced Activity Tumors", Chemistry for the 21st Century, 8	Against Multidrug-Resistan 3-36, 2001.	t Cell Lines and	
	Hofle et al., "Epothilone A and B – Novel Isolation, Crystal Structure, and Conforma 35:1567-1569, 1996.	16-Membered Macrolides w	ith Cytotoxic Activity: em. Int. Ed. Engl.	

FORM PTO-144		ATTY. DOCKET:	IN RE
	Commerce	2003080-0143	APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON9)	NO.: 10/726,386
INFORMATION	I DISCLOSURE STATEMENT	APPLICANT: Danishefsky	et al
(Use sever	al sheets if necessary)	FILING DATE:	GROUP:
		DECEMBER 2, 2003	
70	Hofle, et al., "N-Oxidation of Epothilone A Substituted Epothilones" Angew. Chem. In:		
	Kowalski et al., "Activities of the Microtub		
1	Biol. Chem. 272:4 2534-2541 (1997).		·
	Levin, et al., "An Alternative Procedure for Amides", Synth. Commun. 12: 989, 1982.	the Aluminum-Mediated Co	onversion of Esters to
	Lindel, et al., "Eleutherobin, A New Cytoto Microtubules", J. Am. Chem. Soc. 119: 874		Taxol) by Stabilizing
	Liu et al., "Chiral Synthesis of the C_{3-13} Se (1997)	gment of Epothilone A" Synlo	
	Lythgoe, et al., "Allylic Phosphine Oxides Synthesis of 3-Deoxyvitamin D ₂ ", Tetrahed		
	Lythgoe, et al., "Synthetic Approaches to Vitamin D and its Relatives", Chem. Soc. Rev. 449-475, 1981.		
	March, Advanced Organic Chemistry, 2nd	Ed., McGraw-Hill (1977), pa	ge 940, section 7-21
	Meng et al. "Total Synthesis of Epothilones A and B" J. Am. Chem. Soc. 119:42 10073-10092 (1997).		
	Meng et al. "Studies toward a Synthesis of the Management of Acyclic Stereochemica (1996).		
	Moasser et al., "Farnesyl transferase inhibit Proc. Natl. Acad. Sci. USA, 95:1369-1374		ensitivity to taxol"
	Mooberry, et al., "Laulimalide and Isolauli Stabilizing Agents", Cancer Res. 59: 653-6	malide, New Paclitaxel-Like	Microtubule-
	Muhlradt et al., "Epothilone B Stabilizes M Res. 57, 3344-46 (1997).	icrotubuli of Macrophages L	ike Taxol", Cancer
	Mulzer, J. et al., "Synthesis of the C(1)-C(9) A and B", Tetrahedron Letters 37:51, 9179		Macrolides Epothilon
	Nagaoka, et al., "Further Synthetic Studies 1981.	on Rifamycin S", Tetrahedro	on, 37 : 3873-3888,
	Nahm, et al., "N-Methoxy-N-Methylamide 22: 3815-3818, 1981.	s as Effective Acylating Age	nts", Tetrahedron Lett.
	Nicolaou, et al., "Chemistry and Biology o 1994.	f Taxol", Angew. Chem. Int.	Ed. Engl. 33: 15-44,
	Nicolaou, et al., "Total Synthesis of Epothi through the Stille Coupling Reaction" Angel	lone E and Analogues with New. Chem. Int. Ed., 110: 85-9	Modified Side Chains 2, 1998.
	Nicolaou, K.C. et al. "Total Synthesis of E Chains through the Stille Coupling Reaction	pothilone E and Analogues w	rith Modified Side
	Nicolaou, K.C. et al., "Total Synthesis of E	Spothilone A: The Macrolacto	onization Approach",

DODA PEO 144	40 VIC Donato of	ATTY DOCKET.	IN RE
FORM PTO-144	U.S. Department of Commerce	ATTY. DOCKET: 2003080-0143	APPLICATION
(DEV 9.93)	Patent and Trademark Office		NO.:
(REV. 8-83)	Fatelit and Trademark Office	(SK-744-CON9)	10/726,386
INFORMATIO	N DISCLOSURE STATEMENT	APPLICANT: Danishefsky	y et al
(Use sever	ral sheets if necessary)	FILING DATE:	GROUP:
		DECEMBER 2, 2003	
70	Angew Chem. Int. Ed. Engl., 36:525-527 (1	997).	
	Nicolaou, K.C. et al., "Total Synthesis of C		ontaining Epothilone A
	Analogues", Chem. Eur. J. 3:12 1957-19	70 (1997).	entaining Enathilana D
	Nicolaou, K.C. et al., "Total Synthesis of O Analogues", Chem. Eur. J. 3:12 1971-198	xazole-and Cyclopropalie-C	ontaining Eponnione B
	Nicolaou, K.C. et al., "Designed Epothilone	es: Combinatorial Synthesis.	Tubulin Assembly"
	Agnew Chem. Int. Ed. Engl. 36:19 2097-21		
	Nicolaou, K.C. et al., "Total Synthesis of 2	6-Hydroxy-Epothilone B and	Related Analogs via a
	Macrolactonization Based Strategy" Tetrah	edron 54: 7127-7166 (1998)	
	Nicolaou, K.C. et al. "Total Synthesis of Ep		rolactonization-Based
	Strategy", J. Am. Chem. Soc. 119:7974-799	1 (1997).	1.4
\	Nicolaou, K.C. et al., "Synthesis of Epothil	ones A and B in solid and so	lution phase", Nature
	387:15 268-272, 238-239 (1997). Nicolaou, K.C. et al., "An Approach to Epo	sthilones Based on Olefin Me	etathesis" <i>Ange</i> w
	Chem. Int. Ed. 35:20 2399-2401 (1996).	diffolics Dased on Olemi with	
	Njardarson, et al., "Discovery of Potent Ce	Il Migration Inhibitors Throu	igh Total Synthesis:
	Lessons from Structure - Activity Studies	of (+)- Migrastatin", J. Am. C	Chem. Soc. 126:1038-
	1040, 2004.		
	Noyori, et al., "Asymmetric Hydrogenation	of β-Keto Carboxylic Esters	s. A Practical, Purely
	Chemical Access to β-Hydroxy Esters in H	igh Enantiomeric Purity" J. A	Am. Chem. Soc. 109:
	5856-5859, 1987.	pure Fluorine-Containing Taxoids: Potent Anticancer Agents and	
	Versatile Probes for Biomedical Problems'	, J. Fluorine Chem. 97:3-10,	1999.
	Paterson et al., "Stereocontrolled Aldol Ad	ditions to α-Methylene-β-Al	koxy Aldehydes:
	Application to the Synthesis of a C ₁₃ -C ₂₅ S	egment of Bafilomycin A ₁ "	Tetrahedron Lett.
	36:175-178, 1995.	Compar Call Consult Inhibite	or Dictrostatio 1" I
	Pettet et al., "Isolation and Structure of the Chem. Soc. Chem. Commun. 1111-1112, 1		л Dictyostami i , J.
	Roush et al., "Acyclic Diastereoslective Sy	nthesis Using Tartrate Ester	Modified
	Crotylboronates. Double Asymmetric Rea	ctions with α -Methyl Chiral	Aldehydes and
	Synthesis of the C(19)-C(29) Segment of Rifamycin S" J. Am. Chem. Soc. 112:6348-63		oc. 112:6348-6359,
	Sawada et al., "Enantioselective Total Syn	thesis of Epothilones A and I	B Using
	Multifunctional Asymmetric Catalysis" J Schiff et al., "Promotion of Microtubule A	seembly in vitro by Tayol" A	21-10332, 2000. Jature 277:665-667
	1979.	SSEMBLY III VILLO DY LAXOL A	iuiui 6, 211.005°001,
	Scholl et al., "Increased Ring Closing Met	athesis Activity of Rutheniur	m-Based Olefin
١.	Metathesis Catalysts Coordinated with Imi	dazolin-2-Ylidene Ligands",	Tetrahedron Lett.
\mathbb{A}	40:2247-2250, 1999		·

FORM PTO-1449 U.S. Department of		ATTY. DOCKET:	IN RE
	Commerce	2003080-0143	APPLICATION
(REV. 8-83)	Patent and Trademark Office	(SK-744-CON9)	NO.:
			10/726,386
INFORMATIO	ON DISCLOSURE STATEMENT	APPLICANT: Danishefsky et al	
(Use sev	veral sheets if necessary)	FILING DATE:	GROUP:
		DECEMBER 2, 2003	
1/0	Scudiero et al., "Evaluation of a Soluble To	etrazolium/Formazan Assa	y for Cell Growth and
70	Drug Sensitivity in Culture Using Human a 4833, 1988.	and Other Tumor Cell Line	es", Cancer Res. 48 :4827-
	Schinzer et al., "Studies Toward the Total 2(11):1477-1488, 1996.	·	
	Schinzer et al., "Total Synthesis of (')-Epor 1997.	hilone A" Angew. Chem.	Int. Ed. 36:5 523-524,
	Sefkow et al., "Substitution at the Thiazole 1998.		
	Sinha et al., "Regioselective Synthesis of F Syntheses via Antibody Catalysis" Tetrahe	luoro Aldols. Studies Towderon Letters, 41(43):8243	vard Fluro Epothilones -8246, 2000.
	Stachel et al., "On the Interactivity of Com	plex Synthesis and Tumor	Pharmacology in the
	Drug Discovery Process: Total Synthesis		Evaluations of the 15-Aza
	Epothilones" J. Org. Chem. 66:4369-4378,	2001.	lei Caumling Method
	Su et al., "Total Synthesis of (-) Epothilon and Insights into Structure-Activity Relation	e B: An Extension of the S Inchine of the Enothilones'	' Angew Chem Int Ed
	Engl. 36:757-759, 1997.	diships of the Epotiniones	, Angew. Chem. Int. Du.
	Sun et al. "Stereoselective Total Synthesis	of Epthilones by the Meta	thesis Approach
	involving C9-C10 Bond Formation" Angev	v. Chem. Int. Ed. 8:1381-1	383, 2002.
	Toh et al., "Studies on a Convergent Route Hydroxy-23-Oxavitamin D ₃ " J. Org. Chem	. 48:1414-1417, 1983.	
	Tsuji et al., "Alterations in Cellular Adhes	on and Apoptosis in Epith	elial Cells
	Overexpressing Prostaglandin Endoperoxic	de Synthase 2", Cell, 3:493	5, 1995.
	Victory et al., "Relative Stereochemistry a Like Antimitotic Agent Epothilone A" Bio		
	898, 1996.	organic & medicinal Cher	mon y Denera W(1).073
	Wessjohann, "Epothilones: Promising Natural products with Taxol-Like Activity" Angew. Chem. Int. Ed. Engl. 36(7):715-718, 1997.		
	White et al. "Synthesis, Conformational A D" Organic Letters 4:995-997, 2002.	nalysis, and Bioassay of 9,	10-didehydroepothilone
	Wu et al. "Subtle Variations in the Long-Range Transmission of Stereochemical Information Matched and Mismatched Aldol Reactions" Angew. Chem. Int. Ed. 39(24):4505-4508 (2000)		
V	TARIL		
EXAMINER	1. H. 201014	DATE CONSID	ERED 8-18-05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.